Cabotegravir (Apretude) for HIV-1 Pre-Exposure Prophylaxis

Date: February 21, 2022
Issue #: 
1644Summary: 
The FDA has approvedApretude (ViiV Healthcare),
an IM extended-release (ER) formulation of the integrase
strand transfer inhibitor (INSTI) cabotegravir,
for use every 2 months to prevent sexually acquired
HIV-1 infection in at-risk adolescents and adults.Apretude is the first ER formulation to be FDA-approved
for pre-exposure prophylaxis (PrEP) of
HIV-1 infection.

Source: The Medical Letter - January 25, 2022 Category: Drugs & Pharmacology Authors: admin Tags: Actigall Antihistamines Bylvay Naltrexone odevixibat Rifampin Urso ursodeoxycholic acid Ursodiol Source Type: research